We have been developing an assay for sometime. However now we are about to go into validation we are questioning if it is good enough. 10% of the assays have random wells with high inter-well CV%. We use triplicate wells. This can be as high as 50%. Or just above our limit of 15%. Normal inter-well cv% are really low ( 6 months in small single use aliquots stored at - 80 where low Cvs are through the whole plate.
The assay uses Greiner medium bind.
The antigen is morphine conjugated to BSA coated in carbonate buffer 37°C for one hour at 1 ug/mL
. Block is 0.1% BSA.
Washes three times with statmatic, 300 uL PBS 0.5% Tween20 between each step
primary is a polyclonal rabbit anti morphine 1 hour shaking Room temp
secondary anti-rabbit HRP 1 hour shaking room temp
TMB/Acid
I am about to go through all the numbers to decide whether it is worth proceeding or back to change some aspect of the assay. Of course is business issue of delay to project vs risk of continuing.
What could it be?. Last time it happened the operator reported seeing a little high intensity dot of blue in the TMB incubation in a well that later was twice the OD of it's sister wells. However I cannot say that this was observed in the previous occasions.
It does seem to happen in little spurts, so for three days it is observed, then nothing for two weeks.